

Sub B3
a3
12. (Amended) An adenovirus according to claim 1 [one of the preceding claims], characterized in that the heterologous DNA sequence comprises [contains] one or more genes selected from the group consisting of therapeutic genes and genes encoding antigenic peptides [/or one or more genes encoding antigenic peptides].

13. (Amended) An adenovirus according to claim 12, characterized in that the therapeutic gene is chosen from [the] genes encoding enzymes, blood derivatives, hormones, lymphokines [(interleukins, interferons, TNF and the like)], growth factors, neurotransmitters, precursors of neurotransmitters, synthetic enzymes [or their precursors or synthetic enzymes], trophic factors [(EDNF, CNTF, NGF, IGF, GMF, aFGF, bFGF, NT3, NT5 and the like)], apolipoproteins [(ApoA1, ApoAIV, ApoE and the like)], dystrophin, [or a] minidystrophin, tumor suppressor genes, and [or] genes encoding factors involved in coagulation [(Factors VII, VIII, IX and the like)].

Sub B3
a4
17. (Amended) An adenovirus according to claim 12 [one of the preceding claims], characterized in that the heterologous DNA sequence also comprises sequences permitting the expression of the one or more heterologous genes [therapeutic gene and/or of the gene encoding the antigenic peptide] in the infected cell.

18. (Amended) An adenovirus according to claim 12 [one of the preceding claims], characterized in that the heterologous DNA sequence comprises, upstream of the therapeutic gene, a signal sequence directing the therapeutic product synthesized in the secretory pathways of the target cell.

19. (Amended) A cell line infectible by an adenovirus comprising, integrated into its genome, the functions necessary for the complementation of a defective recombinant adenovirus according to claim 1 [one of claims 1 to 18].

20. (Amended) A cell line according to claim 19, characterized in that it comprises [contains], in its genome[, at least] the E1 and E2 genes from an adenovirus.

Sub D5
Sub B4
21. (Amended) A cell line according to claim 20, characterized in that it additionally comprises [contains, in addition,] the E4 gene from an adenovirus.

22. (Amended) A cell line according to claim 19, characterized in that it comprises [contains, in its genome, at least] the E1 and E4 genes from an adenovirus.

23. (Amended) A cell line according to claim 19 [claims 19 to 22], characterized in that it additionally comprises [contains, in addition,] the gene for the glucocorticoid receptor.

94 Sub D5
24. (Amended) A cell line according to claim 19 [claims 19 to 23], characterized in that the E2 and E4 genes are placed under the control of an inducible promoter.

26. (Amended) A cell line according to claim 19 [claims 19 to 25], characterized in that the E2 gene encodes the 72 K protein.

27. (Amended) A cell line according to claim 19 [claims 19 to 26], characterized in that it is obtained from the line 293.

28. (Amended) A pharmaceutical composition comprising at least one defective recombinant adenovirus according to claim 1 [one of claims 1 to 18].

29. (Amended) A pharmaceutical composition [according to claim 28], comprising a recombinant adenovirus according to claim 5 [one of claims 5 to 10].

30. (Amended) A pharmaceutical composition according to claim 28 [claims 28 or 29], comprising a vehicle pharmaceutically acceptable for an injectable formulation.

In the Specification:

At page 27, line 14, please insert --(SEQ ID No. 1)-- after "orientation:".

Please insert the attached SEQUENCE LISTING after page 29 of the English Translation of the International Application. Please renumber the CLAIMS and ABSTRACT pages.


REMARKS

Applicants have amended the claims to conform with U.S. patent practice. No new matter has been added. For the convenience of the Examiner, the amended claims are attached hereto as an Appendix.

Applicants have submitted a SEQUENCE LISTING pursuant to 37 CFR §§ 1.821-1.825. No new matter has been added.

Rhône-Poulenc Rorer, Inc.
500 Arcola Road, 3C43
Collegeville, PA 19426-0107
Telephone: (610) 454-3839
Facsimile: (610) 454-3808

Respectfully submitted,



Dated: 10 March 1995

Julie K. Smith, Ph.D.
Agent for Applicants
Registration No. 38,619